Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 1998

View Archived Issues

MedImmune: Q3 1998 highlights

Aquila Biopharmaceuticals: Q3 1998 highlights

Sepracor: Q3 1998 highlights

MitoKor and Pfizer to collaborate on mitochondrial targets for neurodegenerative diseases

Two major clinical studies demonstrate chemo- and radioprotective activity of amifostine

FAME study will evaluate effects of lipid lowering in the elderly

Sangamo enters agreement with Zeneca for identification of novel gene targets

BMS to acquire Korean company

Promising interim results announced for SU-5416 phase I trial

WAY-135433 increases HDL cholesterol, protects against atherosclerosis and heart disease

Novel compounds from ADIR acting on the dopaminergic system

Compounds acting on metabotropic glutamate receptors disclosed by Lilly

Noncytotoxic thiocolchicine derivatives useful as muscle relaxants

Canadian team describes cardioprotective activity of AAA-135

New series from Agouron with inhibitory activity against MMPs and TNF-alpha production

Pharmacia & Upjohn patents new agents for CNS and neurodegenerative disorders

Specific MC4 receptor agonist reduces food intake in leptin-deficient and -resistant mice

LY-203638 has potent profibrinolytic effects in canine model of thrombosis

Pfizer presents preclinical profile of potent, full 5-HT1D receptor antagonist

RPR-118723: a novel anticonvulsant and potent glycine-site NMDA receptor antagonist

Knoll's promising new treatment for RA covered in depth at rheumatology congress

Reversible mixed MAO-A/MAO-B inhibitor discovered at Synthelabo is presented this week

Novel sodium channel blocker from Roche evaluated in vitro for neuroprotective efficacy

NK1 antagonist L-732138 exhibits activity indicating efficacy in neuropathic pain

Cevimeline improves symptoms of xerostomia in animal models, patients with Sjogren's syndrome

LEF-553: a potent mu-opioid receptor agonist with peripheral analgesic effects

Preclinical pharmacokinetics of MEN-11420 determined in rats; compound advances to clinical trials

Ciba Vision launches Vitravene in the U.S.

Knoll develops potential new antipsychotic agent with advantages over available therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...